Fenofibrate + simvastatin fixed-combination versus monotherapies in mixed dyslipidemia

Phase 3, randomised, double-blind trial of simvastatin + fenofibrate, simvastatin and fenofibrate in combined dyslipidaemia and dyslipidemia (4 arms), sponsored by Abbott Laboratories. Primary endpoints: Percent change in triglycerides from baseline to Week 12, Percent change in high-density lipoprotein cholesterol from baseline to Week 12 and 1 more. Started Mar 2012; status: completed.